Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 11/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
| ▸ | PYGM | P11217 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2282815 | 1.00 | SCN9A (0.43) | SCN9ARIPK1MEN1KMT2ADRD4 | |
| SCHEMBL17312390 | 0.83 | MEN1 (0.39) | RIPK1MEN1KMT2APYGLPYGM | |
| SCHEMBL17312764 | 0.80 | MAPT (0.41) | RIPK1 | |
| SCHEMBL17312786 | 0.80 | RIPK1 (0.39) | SCN9ARIPK1 | |
| SCHEMBL2235808 | 0.80 | RIPK1 (0.39) | SCN9ARIPK1 | |
| SCHEMBL17312359 | 0.79 | NR1H3 (0.41) | SCN9A | |
| SCHEMBL1999440 | 0.79 | RIPK1 (0.42) | RIPK1MEN1KMT2A | |
| SCHEMBL1999442 | 0.79 | RIPK1 (0.42) | RIPK1MEN1KMT2A | |
| SCHEMBL7246586 | 0.78 | CHRM2 (0.52) | MEN1KMT2A | |
| SCHEMBL2279348 | 0.78 | NPY1R (0.45) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3508484-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-07-10 | — | — | EP | disclosed |
| US-9556152-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-31 | — | — | US | disclosed |
| US-20150353533-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-10 | — | — | US | disclosed |
| US-7994162-B2 | 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzazepines, the preparation and use thereof, and compositions containing the same | SANOFI-AVENTIS (FR) | 2011-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353533-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP3K3 | SCN9A 3929/4885RIPK1 349/4885MEN1 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.